With support from the President’s Malaria Initiative (PMI), PQM+ is working with DRC’s national medicines regulatory authority (Autorité Congolaise de Réglementation Pharmaceutique, ACOREP) to help ensure the quality of medical products in country, such as antimalarial medicines, by strengthening its post-marketing surveillance (PMS) function, which includes adopting a risk-based approach to PMS and establishing a national PMS technical working group. PQM+ will also help ACOREP conduct national risk-based post-marketing surveillance (RB-PMS) of selected medicines to treat malaria. RB-PMS allows governments to channel limited resources to medicines and locations that pose the highest risk to the public.
